CPX 351 As First Line Treatment in Higher Risk MDS. a Phase II Trial By the GFM

▪ Background and aims: intensive chemotherapy (IC) has been used since the early 90's in the treatment of higher risk MDS, yielding 40 to 50% complete response (CR) but prolonged myelosuppression and 10 to 30% early deaths. IC is also recommended before allogeneic (allo) SCT when marrow blasts...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2021-11, Vol.138 (Supplement 1), p.243-243
Main Authors: Peterlin, Pierre, Turlure, Pascal, Chevallier, Patrice, Gourin, Marie-Pierre, Dumas, Pierre-Yves, Thepot, Sylvain, Berceanu, Anna, Park, Sophie, Hospital, Marie Anne, Cluzeau, Thomas, Torregrosa Diaz, Jose Miguel, Devron, Louis, Chevret, Sylvie, Bene, Marie C, Le Bris, Yannick, Sapena, Rosa, Chermat, Fatiha, Dimicoli-Salazar, Sophie, Fenaux, Pierre
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:▪ Background and aims: intensive chemotherapy (IC) has been used since the early 90's in the treatment of higher risk MDS, yielding 40 to 50% complete response (CR) but prolonged myelosuppression and 10 to 30% early deaths. IC is also recommended before allogeneic (allo) SCT when marrow blasts are increased (De Witte et al, Blood, 2017). CPX-351, a liposomal combination of cytarabine and daunorubicin, proved greater efficacy than classical IC with 3+7 in secondary-AML, including in patients with 20-30% marrow blasts and those who subsequently received allo SCT (Lancet et al, Lancet Haematol, 2021). We evaluated response to CPX-351 in a group of untreated higher risk MDS patients, most of whom were candidates for allo SCT. Methods: This prospective study, involving 12 GFM centers, included int-2 or high IPSS MDS, previously untreated with HMA or chemotherapy, and aged
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2021-145123